We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corcept Therapeutics (CORT - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Corcept Therapeutics is a member of the Medical sector. This group includes 914 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Corcept Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CORT's full-year earnings has moved 142% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that CORT has returned about 161.2% since the start of the calendar year. In comparison, Medical companies have returned an average of -1.2%. This means that Corcept Therapeutics is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Quest Diagnostics (DGX - Free Report) . The stock is up 20.9% year-to-date.
For Quest Diagnostics, the consensus EPS estimate for the current year has increased 0.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Corcept Therapeutics is a member of the Medical - Drugs industry, which includes 137 individual companies and currently sits at #93 in the Zacks Industry Rank. On average, this group has lost an average of 4.2% so far this year, meaning that CORT is performing better in terms of year-to-date returns.
Quest Diagnostics, however, belongs to the Medical - Outpatient and Home Healthcare industry. Currently, this 14-stock industry is ranked #95. The industry has moved +18.1% so far this year.
Corcept Therapeutics and Quest Diagnostics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corcept Therapeutics (CORT - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Corcept Therapeutics is a member of the Medical sector. This group includes 914 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Corcept Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CORT's full-year earnings has moved 142% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that CORT has returned about 161.2% since the start of the calendar year. In comparison, Medical companies have returned an average of -1.2%. This means that Corcept Therapeutics is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Quest Diagnostics (DGX - Free Report) . The stock is up 20.9% year-to-date.
For Quest Diagnostics, the consensus EPS estimate for the current year has increased 0.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Corcept Therapeutics is a member of the Medical - Drugs industry, which includes 137 individual companies and currently sits at #93 in the Zacks Industry Rank. On average, this group has lost an average of 4.2% so far this year, meaning that CORT is performing better in terms of year-to-date returns.
Quest Diagnostics, however, belongs to the Medical - Outpatient and Home Healthcare industry. Currently, this 14-stock industry is ranked #95. The industry has moved +18.1% so far this year.
Corcept Therapeutics and Quest Diagnostics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.